Bruce Bode, MD
Atlanta Diabetes Associates
Michael Silver, MD
Medical Director, United Health Care, New York
Richard Weiss, MS
Managed Solutions, Mount Freedom, New Jersey
Kathryn Martin
PharmD, Managed Solutions, Mount Freedom, New Jersey

Bruce Bode, MD

Atlanta Diabetes Associates

Michael Silver, MD

Medical Director, United Health Care, New York

Richard Weiss, MS

Managed Solutions, Mount Freedom, New Jersey

Kathryn Martin

PharmD, Managed Solutions, Mount Freedom, New Jersey

Introduction

The cost burden of diabetes is significant. In 2007, the total costs associated with the disease were estimated at $174 billion (ADA 2008). Patients diagnosed with diabetes incur 2.3 times higher medical expenditures than those without the disease. Hypoglycemia severe enough to warrant third-party intervention results in mean costs exceeding $1,000 per episode (Bullano 2005, Heaton 2003).

Several landmark trials have confirmed that tighter control of diabetes improves clinical outcomes (UKPDS Group 1998, DCCTRG 1993). The adoption of an intensive form of diabetes management can, however, come with increased risk, as was reported in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial (NHLBI 2008). There is speculation that the increased risk of cardiovascular death may be due to higher baseline cardiovascular risk; however, this has yet to be confirmed. Intensive management of diabetes would, therefore, require close monitoring of glycemic control with the goal of maintaining blood glucose levels within a defined optimal range (70–180 mg/dL) (ADA 2005).

Continuous glucose monitoring (CGM) provides greater information regarding glycemic control than episodic blood glucose measurements. CGM has the ability to indicate a rate of change both in numeric form and through the use of prospective, directional trend arrows. In addition, alarms are activated when glucose levels approach critical hypoglycemic or hyperglycemic values. CGM provides the patient and health care provider with access to retrospective continuous glucose data over clinically relevant periods of time (Garg 2006, Deiss 2006). These features result in systems that provide trend information that can guide treatment decision making.

This is a report of a study examining the accuracy of the FreeStyle Navigator Continuous Glucose Monitoring System (Abbott Diabetes Care, Abbott Park, Ill.) in the home environment and patient assessment of its use. The device and its performance in a clinical setting have been described previously (Weinstein 2007).

Managed Care’s Top Ten Articles of 2016

There’s a lot more going on in health care than mergers (Aetna-Humana, Anthem-Cigna) creating huge players. Hundreds of insurers operate in 50 different states. Self-insured employers, ACA public exchanges, Medicare Advantage, and Medicaid managed care plans crowd an increasingly complex market.

Major health care players are determined to make health information exchanges (HIEs) work. The push toward value-based payment alone almost guarantees that HIEs will be tweaked, poked, prodded, and overhauled until they deliver on their promise. The goal: straight talk from and among tech systems.

They bring a different mindset. They’re willing to work in teams and focus on the sort of evidence-based medicine that can guide health care’s transformation into a system based on value. One question: How well will this new generation of data-driven MDs deal with patients?

The surge of new MS treatments have been for the relapsing-remitting form of the disease. There’s hope for sufferers of a different form of MS. By homing in on CD20-positive B cells, ocrelizumab is able to knock them out and other aberrant B cells circulating in the bloodstream.

A flood of tests have insurers ramping up prior authorization and utilization review. Information overload is a problem. As doctors struggle to keep up, health plans need to get ahead of the development of the technology in order to successfully manage genetic testing appropriately.

Having the data is one thing. Knowing how to use it is another. Applying its computational power to the data, a company called RowdMap puts providers into high-, medium-, and low-value buckets compared with peers in their markets, using specific benchmarks to show why outliers differ from the norm.
Competition among manufacturers, industry consolidation, and capitalization on me-too drugs are cranking up generic and branded drug prices. This increase has compelled PBMs, health plan sponsors, and retail pharmacies to find novel ways to turn a profit, often at the expense of the consumer.
The development of recombinant DNA and other technologies has added a new dimension to care. These medications have revolutionized the treatment of rheumatoid arthritis and many of the other 80 or so autoimmune diseases. But they can be budget busters and have a tricky side effect profile.

Shelley Slade
Vogel, Slade & Goldstein

Hub programs have emerged as a profitable new line of business in the sales and distribution side of the pharmaceutical industry that has got more than its fair share of wheeling and dealing. But they spell trouble if they spark collusion, threaten patients, or waste federal dollars.

More companies are self-insuring—and it’s not just large employers that are striking out on their own. The percentage of employers who fully self-insure increased by 44% in 1999 to 63% in 2015. Self-insurance may give employers more control over benefit packages, and stop-loss protects them against uncapped liability.